Cytokinetics, Inc. : Cytokinetics to Present at 8th Annual JMP Securities Healthcare Conference

  Cytokinetics, Inc. : Cytokinetics to Present at 8th Annual JMP Securities
                            Healthcare Conference

South San Francisco, CA,  July 1, 2013  - Cytokinetics, Incorporated  (Nasdaq: 
CYTK) announced  today that  Robert  I. Blum,  President and  Chief  Executive 
Officer, is scheduled  to present a  corporate update at  the 8^th Annual  JMP 
Securities Healthcare  Conference  on Wednesday,  July  10, 2013  at  2:30  PM 
Eastern time at the St. Regis in New York, NY.

Interested parties  may  access the  live  audio  and slide  webcast  of  this 
presentation by visiting  the Investor Relations  section of the  Cytokinetics 
website at www.cytokinetics.com. The webcast  replay of the presentation  will 
be archived on the Presentations page within the Investor Relations section of
Cytokinetics' website for two weeks following the completion of the event.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function  for the  potential treatment  of serious  diseases and  other 
medical conditions. Cytokinetics  currently has three  compounds in  clinical 
development: omecamtiv  mecarbil  in Phase  II  for acute  and  chronic  heart 
failure,  tirasemtiv  in  Phase  II  for  amyotrophic  lateral  sclerosis  and 
CK-212107 in a Phase I study in healthy volunteers. All of the company's  drug 
candidates have  arisen from  Cytokinetics'  muscle biology  focused  research 
activities and are directed  towards the cytoskeleton.  The cytoskeleton is  a 
complex biological infrastructure that plays  a fundamental role within  every 
human cell.  Additional information  about Cytokinetics  can be  obtained  at 
http://www.cytokinetics.com.

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates.  Such 
statements are based on management's current expectations, but actual  results 
may differ materially due to  various risks and uncertainties, including,  but 
not limited to, potential difficulties or delays in the development,  testing, 
regulatory approval  and  production  of  Cytokinetics'  drug  candidates  and 
potential drug candidates that could  slow or prevent clinical development  or 
product approval, including risks  that current and  past results of  clinical 
trials or preclinical studies may not be indicative of future clinical  trials 
results and that Cytokinetics' drug  candidates and potential drug  candidates 
may have unexpected adverse side  effects or inadequate therapeutic  efficacy. 
For  further  information   regarding  these  and   other  risks  related   to 
Cytokinetics' business, investors  should consult  Cytokinetics' filings  with 
the Securities and Exchange Commission.

Contacts:
Cytokinetics, Incorporated:      
Joanna L. Goldstein   
Manager, Investor Relations & Corporate Communications
(650) 624-3000

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1713459
 
Press spacebar to pause and continue. Press esc to stop.